Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
NCT04997993Phase 1Recruiting
- Start
- Dec 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in solid tumor and breast cancer. Primary endpoint: Dose-limiting toxicities at 1 month. Started Dec 2023; status: recruiting.
02
Drugs
leflunomide
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04997993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997993.